PL3727349T3 - Nanocząstki do zastosowania do leczenia zaburzenia neuronalnego - Google Patents
Nanocząstki do zastosowania do leczenia zaburzenia neuronalnegoInfo
- Publication number
- PL3727349T3 PL3727349T3 PL18822053.7T PL18822053T PL3727349T3 PL 3727349 T3 PL3727349 T3 PL 3727349T3 PL 18822053 T PL18822053 T PL 18822053T PL 3727349 T3 PL3727349 T3 PL 3727349T3
- Authority
- PL
- Poland
- Prior art keywords
- nanoparticles
- treatment
- neuronal disorders
- neuronal
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nanotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17306826 | 2017-12-19 | ||
| PCT/EP2018/085593 WO2019121748A1 (en) | 2017-12-19 | 2018-12-18 | Nanoparticles for use for treating a neuronal disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3727349T3 true PL3727349T3 (pl) | 2025-02-10 |
Family
ID=60954823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18822053.7T PL3727349T3 (pl) | 2017-12-19 | 2018-12-18 | Nanocząstki do zastosowania do leczenia zaburzenia neuronalnego |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11497717B2 (pl) |
| EP (1) | EP3727349B1 (pl) |
| JP (3) | JP7424640B2 (pl) |
| KR (1) | KR102729931B1 (pl) |
| CN (1) | CN111886004A (pl) |
| AU (1) | AU2018391789B2 (pl) |
| BR (1) | BR112020012214A2 (pl) |
| ES (1) | ES2991899T3 (pl) |
| HU (1) | HUE068741T2 (pl) |
| IL (1) | IL275408B2 (pl) |
| MX (1) | MX2020006360A (pl) |
| PL (1) | PL3727349T3 (pl) |
| PT (1) | PT3727349T (pl) |
| UA (1) | UA128390C2 (pl) |
| WO (1) | WO2019121748A1 (pl) |
| ZA (1) | ZA202004344B (pl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2998117T3 (en) | 2017-12-19 | 2025-02-19 | Nanobiotix | Nanoparticles for use in enhancing brain performances or in treating stress |
| CA3084780A1 (en) * | 2020-06-24 | 2021-12-24 | Rodney HERRING | Use of low iron oxide iron-doped titanium dioxide nanoparticles in the treatment of tumors and other diseases |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3835A (en) | 1844-11-26 | Improvement in cotton-presses | ||
| CA2664919A1 (en) | 2006-08-08 | 2008-02-21 | Board Of Regents Of The University Of Texas | Multistage delivery of active agents |
| WO2009052295A2 (en) | 2007-10-16 | 2009-04-23 | Edward Via Virginia College Of Osteopathic Medicine | Cerium oxide nanoparticles for treatment and prevention of alzheimer's disease, parkinson's disease, and disorders associated with free radical production and/or mitochondrial dysfunction |
| WO2010054017A1 (en) | 2008-11-04 | 2010-05-14 | Nikolaos Tezapsidis | Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta |
| KR101931381B1 (ko) | 2009-07-08 | 2018-12-20 | 클레네 나노메디슨, 인크. | 의학적 치료를 위한 신규한 금계 나노결정 및 이를 위한 전기화학 제조 방법 |
| EP2540169B1 (en) | 2010-02-26 | 2016-07-06 | Universidad de Navarra | Nanoparticles for the encapsulation of compounds, preparation thereof and use of same |
| PL2670394T3 (pl) | 2011-01-31 | 2019-03-29 | Nanobiotix | Układy do dostarczania nanocząstek, ich otrzymywanie i zastosowania |
| MX2014015251A (es) | 2012-06-13 | 2015-04-13 | Cerion Entpr Llc | Nanocerios para el tratamiento del estres oxidativo. |
| EP2974717A3 (en) | 2014-07-16 | 2016-04-13 | GNT Biotech & Medicals Corporation | Use of nano metal in promoting neurite outgrowth and treatment and/or prevention of neurological disorders |
| WO2016083336A1 (en) * | 2014-11-25 | 2016-06-02 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
| WO2017060916A1 (en) | 2015-10-09 | 2017-04-13 | NOUSHAD Javed Md | Metallic nanoparticle alone and/or in combination as novel agent for the treatment of uncontrolled electric conductance related disorders and/or seizure, epilepsy & convulsions. |
| US20170290916A1 (en) | 2016-04-07 | 2017-10-12 | The Florida International University Board Of Trustees | Materials and Methods for the Delivery of a Nanocarrier to the Brain |
| JP7766899B2 (ja) * | 2016-12-21 | 2025-11-11 | ナノビオティックス | 神経障害を処置するのに使用するためのナノ粒子 |
| EA201991521A1 (ru) | 2016-12-21 | 2019-12-30 | Нанобиотикс | Наночастицы для применения для улучшения деятельности мозга или для лечения стресса |
| WO2018115023A1 (en) | 2016-12-21 | 2018-06-28 | Nanobiotix | Coated nanoparticles for use for modulating electrical polarization of neurons |
| ES2998117T3 (en) | 2017-12-19 | 2025-02-19 | Nanobiotix | Nanoparticles for use in enhancing brain performances or in treating stress |
| US20200015750A1 (en) | 2018-07-11 | 2020-01-16 | Patriot Worldwide, Inc. | Needle assembly with temperature measurement device |
-
2018
- 2018-12-18 CN CN201880086897.0A patent/CN111886004A/zh active Pending
- 2018-12-18 HU HUE18822053A patent/HUE068741T2/hu unknown
- 2018-12-18 WO PCT/EP2018/085593 patent/WO2019121748A1/en not_active Ceased
- 2018-12-18 PL PL18822053.7T patent/PL3727349T3/pl unknown
- 2018-12-18 IL IL275408A patent/IL275408B2/en unknown
- 2018-12-18 PT PT188220537T patent/PT3727349T/pt unknown
- 2018-12-18 EP EP18822053.7A patent/EP3727349B1/en active Active
- 2018-12-18 BR BR112020012214-9A patent/BR112020012214A2/pt unknown
- 2018-12-18 KR KR1020207019895A patent/KR102729931B1/ko active Active
- 2018-12-18 UA UAA202004468A patent/UA128390C2/uk unknown
- 2018-12-18 US US16/955,092 patent/US11497717B2/en active Active
- 2018-12-18 ES ES18822053T patent/ES2991899T3/es active Active
- 2018-12-18 MX MX2020006360A patent/MX2020006360A/es unknown
- 2018-12-18 JP JP2020533801A patent/JP7424640B2/ja active Active
- 2018-12-18 AU AU2018391789A patent/AU2018391789B2/en active Active
-
2020
- 2020-07-15 ZA ZA2020/04344A patent/ZA202004344B/en unknown
-
2024
- 2024-01-11 JP JP2024002499A patent/JP7725096B2/ja active Active
-
2025
- 2025-07-30 JP JP2025127249A patent/JP2025163111A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3727349B1 (en) | 2024-08-07 |
| ES2991899T3 (es) | 2024-12-05 |
| JP2025163111A (ja) | 2025-10-28 |
| KR102729931B1 (ko) | 2024-11-13 |
| US20210015756A1 (en) | 2021-01-21 |
| IL275408B2 (en) | 2024-06-01 |
| HUE068741T2 (hu) | 2025-01-28 |
| JP7424640B2 (ja) | 2024-01-30 |
| JP2024038335A (ja) | 2024-03-19 |
| UA128390C2 (uk) | 2024-07-03 |
| KR20200110321A (ko) | 2020-09-23 |
| ZA202004344B (en) | 2023-10-25 |
| IL275408B1 (en) | 2024-02-01 |
| IL275408A (en) | 2020-07-30 |
| JP7725096B2 (ja) | 2025-08-19 |
| NZ766044A (en) | 2025-09-26 |
| EP3727349A1 (en) | 2020-10-28 |
| US11497717B2 (en) | 2022-11-15 |
| BR112020012214A2 (pt) | 2020-11-24 |
| RU2020123702A (ru) | 2022-01-21 |
| CA3085528A1 (en) | 2019-06-27 |
| CN111886004A (zh) | 2020-11-03 |
| WO2019121748A1 (en) | 2019-06-27 |
| AU2018391789A1 (en) | 2020-07-23 |
| MX2020006360A (es) | 2020-08-17 |
| PT3727349T (pt) | 2024-10-31 |
| RU2020123702A3 (pl) | 2022-01-21 |
| AU2018391789B2 (en) | 2024-05-23 |
| JP2021506873A (ja) | 2021-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2023010I1 (el) | Προφαρμακα καρβιντοπας και l-ντοπας και η χρηση τους στην αγωγη της νοσου parkinson | |
| IL279752A (en) | Polycyclic compounds and use thereof in the treatment of immune disorders | |
| HUE061761T2 (hu) | Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében | |
| IL263484A (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| HRP20190117T1 (hr) | iRNK TERAPIJA ZA LIJEČENJE BOLESTI OKA | |
| PL3157512T3 (pl) | Zastosowanie kannabidioli w leczeniu padaczki | |
| GB2542155B (en) | Use of cannabidiol in the treatment of mental disorders | |
| HUE050095T2 (hu) | Anyagcsere-rendellenességek kezelése lófélékben | |
| HUE059559T2 (hu) | 5HT agonisták az epilepsziás rendellenességek kezelésére | |
| PT3119397T (pt) | Compostos heterocíclicos para utilização no tratamento de distúrbios mediados por pi3k-gama | |
| EP3539600C0 (en) | DEVICE SUITABLE FOR USE IN THE TREATMENT OF RESPIRATORY DISEASES | |
| EP3448263A4 (en) | ELECTROTHERAPEUTIC TREATMENT | |
| PL3503890T3 (pl) | Stosowanie pridopidyny w leczeniu dystonii | |
| HRP20180260T1 (hr) | Dimer buprenorfina i njegova uporaba u liječenju gastrointestinalnih poremećaja | |
| HRP20180337T1 (hr) | Kalcitonin mimetika za liječenje bolesti i poremećaja | |
| PL3236960T3 (pl) | Fluralaner do zastosowania w leczeniu demodekozy | |
| PL3432872T3 (pl) | Eflornityna do zastosowania w leczeniu nawracającego/opornego na leczenie temozolomidem gwiaździaka anaplastycznego | |
| IL270900A (en) | Treatment of cutaneous disorders | |
| HUE039750T2 (hu) | Hidroxi-buspiron mozgászavarok kezelésére | |
| IL280227A (en) | Arimoclomol for treating glucocerebrosidase associated disorders | |
| IL260987A (en) | Treatment and diagnosis of inflammatory disorders | |
| EP3373888A4 (en) | METHOD FOR THE TREATMENT OF SKIN DISEASES USING PLASMONIC NANOPARTICLES | |
| IL263080B (en) | Treatment of neurological disorders | |
| GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
| PL3727349T3 (pl) | Nanocząstki do zastosowania do leczenia zaburzenia neuronalnego |